Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder characterized by cognitive decline and memory impairment. With increasing global prevalence, the need for effective therapeutic interventions is critical. Among the currently approved treatments, acetylcholinesterase inhibitors (AChEIs) like huperzine A and galantamine stand out due to their neuroprotective roles. These plant-derived alkaloids have demonstrated significant efficacy in alleviating symptoms by increasing acetylcholine levels in the brain.

While numerous other plant alkaloids exhibit varying degrees of neuroactive properties, huperzine A and galantamine remain the only plant-derived alkaloids currently approved and marketed as specific treatments for AD and other neurodegenerative diseases. For example, alkaloids such as berberine (from Berberis species) and rhynchophylline (from Uncaria rhynchophylla) have shown potential in targeting amyloid-beta (Aβ) aggregation, oxidative stress, and tau hyperphosphorylation. Similarly, harmine has demonstrated the ability to inhibit tau hyperphosphorylation through dual inhibition of glycogen synthase kinase-3 beta (GSK-3β) and dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A). However, these metabolites have not yet advanced to clinical applications (Ng et al., 2015; Rezaul Islam et al., 2024).

The elucidation of the biosynthetic pathways of huperzine A and galantamine marks a significant advancement in understanding plant biochemistry and specialized metabolism. It not only advances our understanding of plant-derived neuroactive metabolites but also provides opportunities for sustainable and scalable production through synthetic biology approaches. By leveraging this approach, researchers can reconstruct the biosynthetic pathways of plant-derived natural products in microbial or plant systems, facilitating efficient production and reducing the reliance on native plant sources for these valuable compounds (Liu et al., 2023; Zhang et al., 2023; Bai et al., 2024; Teng et al., 2024). This opinion highlights the implications of these discoveries for future research and application in neurodegenerative disease treatment.

The elucidation of huperzine A and galantamine biosynthetic pathways underscores the complexity and elegance of plant specialized metabolism. Both alkaloids share the common feature of acting as acetylcholinesterase inhibitors, though their evolutionary and biosynthetic origins differ significantly. The Lycopodium and Amaryllidaceae families, through distinct evolutionary pressures, have developed highly specialized enzymes that allow these plants to synthesize neuroactive metabolites with intricate polycyclic structures. While the elucidation of these biosynthetic pathways represents a significant advancement, several challenges remain.

First, the in vivo functional roles of these alkaloids in plants are not fully understood. It is speculated that they serve as defense metabolites against herbivores, but the regulatory mechanisms governing their production remain elusive (Chavez et al., 2024). Further research into the ecological roles of these alkaloids could provide important insights into the evolution of medicinal plants, the evolution of biosynthetic pathways, and their interactions with the environment (Szypuła and Pietrosiuk, 2023; Zhang et al., 2024).

Second, the scalability of producing huperzine A and galantamine through heterologous systems remains a key challenge. While transient expression in N. benthamiana has demonstrated proof-of-concept for biosynthesis, translating these findings into industrial-scale production will require optimization of gene expression, precursor supply, and enzymatic activity in microbial or plant-based platforms (Liu J. C. et al., 2024; Yang et al., 2024). Optimizing precursor supply, enhancing enzyme activity, and achieving high-yield production in heterologous systems are critical bottlenecks. Microbial synthetic biology platforms, such as Saccharomyces cerevisiae and Pichia pastoris, offer promising avenues for large-scale production due to their scalability and ease of genetic manipulation (Zhang et al., 2022; Gao et al., 2023; Yang et al., 2024). On the other hand, plant chassis like N. benthamiana provide unique advantages, including natural metabolic environments and compartmentalized cells conducive to complex biosynthesis (Liu et al., 2023; Zhang et al., 2023; Golubova et al., 2024; Liu J. C. et al., 2024). Advances in CRISPR-based genome editing, multi-gene pathway assembly, and metabolic flux optimization are pivotal for overcoming current limitations (Liao et al., 2023; Xie et al., 2023; Teng et al., 2024). By leveraging these tools, researchers can create efficient production platforms not only for huperzine A and galantamine but also for other plant-derived neuroactive alkaloids, paving the way for accessible and sustainable therapeutics for Alzheimer’s disease.

Finally, the potential for discovering new neuroactive alkaloids in related plant species should not be overlooked. The pathways for huperzine A and galantamine likely represent only a fraction of the neuroactive metabolites that plants produce. Systematic exploration of the metabolic pathways in related species could yield novel AChE inhibitors or other metabolites targeting neurodegenerative diseases.

The elucidation of the biosynthetic pathways of huperzine A and galantamine marks a pivotal moment in plant biochemistry and neuropharmacology. These discoveries not only deepen our understanding of plant metabolism but also offer practical pathways for the sustainable production of crucial AD treatments. As the global population ages and the burden of neurodegenerative diseases grows, plant-derived neuroactive alkaloids like huperzine A and galantamine will continue to play an essential role in treatment. The future of this research lies in the intersection of synthetic biology, metabolic engineering, and traditional plant sciences, paving the way for innovative solutions to Alzheimer’s disease and other neurological disorders.